<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00701792</url>
  </required_header>
  <id_info>
    <org_study_id>N/1993/04</org_study_id>
    <nct_id>NCT00701792</nct_id>
  </id_info>
  <brief_title>Liver Transplantation Versus Alternative Therapies for Patients With Pugh B Alcoholic Cirrhosis</brief_title>
  <acronym>TRANSCIAL</acronym>
  <official_title>Randomized Trial Comparing Liver Transplantation to Alternative Therapies for Patients With Pugh B Alcoholic Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Liver transplantation has been universally recognized to improve survival of patients
      suffering from end-stage (Pugh C) alcoholic cirrhosis. However, for Pugh B patients, the
      benefit of liver transplantation remains to be demonstrated. The aim of the present study was
      to compare the outcome of Pugh B patients with alcoholic cirrhosis randomly assigned for
      immediate liver transplantation (group 1) or standard treatments (group 2).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      120 patients (60 per group) were included. The therapeutic strategy defined by randomization
      was achieved in 68% of group 1 patients and 75% of group 2 patients (NS). All-causes death
      and cirrhosis-related death were not different in group 1 and group 2 patients: the five-year
      survival rate was 58% in group 1 and 69% in group 2 patients (NS). Through multivariate
      analysis, the independent predictors of long-term survival were absence of ongoing alcohol
      consumption (p&lt;0.001), recovery from Pugh C (p=0.046), and baseline Pugh score&lt;8 (p=0.029).
      Liver transplantation was associated with a higher rate of de novo malignancies (30.4% vs.
      7.8%, OR=5.1, p=0.001).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1994</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>all causes mortality</measure>
    <time_frame>five years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>surgery : liver transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard care for liver disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>liver transplantation</intervention_name>
    <description>liver transplantation</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard care for liver disease</intervention_name>
    <description>standard care for liver disease included therapy for ascitis (spironolactone, furosemide), portal hypertension (oesophageal varices ; propranolol), encephalopathy (lactulose), and bacterial infections whatever their localization (prophylaxis of spontaneous peritonitis with norfloxacin). All medical or instrumental procedures were allowed. Patients undergoing iterative paracentesis, variceal band ligation or sclerotherapy, peritoneojugular shunt (LeVeen), transjugular intrahepatic portosystemic shunt (TIPS) or surgical portocaval anastomosis were considered as receiving &quot;standard medical therapy&quot;.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  cirrhosis

          -  age 18-65yrs

          -  Pugh B

          -  written consent

        Exclusion Criteria:

          -  HIV, HBV or HCV infection

          -  hepatocellular carcinoma

          -  Pugh A or Pugh C cirrhosis

          -  creatinin &gt;200µMol/L

          -  sepsis

          -  psychiatric disorders

          -  extrahepatic neoplasia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Phillipe MIGUET</last_name>
    <role>Study Chair</role>
    <affiliation>Service d'Hépatologie - CHU de Besançon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>service d'hépatologie CHU jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU CAEN - Service d'hépato-gastroentérologie</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon - Hépato-gastroentérologie</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Henri Mondor - Hépato-gastroentérologie</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hépato-gastroenterologie CHU Bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre d'épidémiologie de population EPI 106</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bon secours - Hépato-gastroentérologie</name>
      <address>
        <city>Metz</city>
        <zip>57000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Eloi - Hépato-gastroentérologie</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié-Salpétrière - Hépato-gastroentérologie</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hepato-gastroenterologie</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Reims - hépato-gestroentérologie</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique des maladies du foie Hôpital Pontchailloux</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Purpan - Hépato-gastroentérologie</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2008</study_first_submitted>
  <study_first_submitted_qc>June 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2008</study_first_posted>
  <last_update_submitted>June 18, 2008</last_update_submitted>
  <last_update_submitted_qc>June 18, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2008</last_update_posted>
  <responsible_party>
    <name_title>M. FLAMMARION - Directeur des Projets, de la Recherche CLinique et de l'Innovation</name_title>
    <organization>Centre Hospitalier Universitaire de Besancon</organization>
  </responsible_party>
  <keyword>cirrhosis transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Cirrhosis, Alcoholic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

